MetaCap

Shattuck Labs Inc. (STTK)

NASDAQ: STTKHealth CareBiotechnology: Pharmaceutical PreparationsUSD

4.46-0.09 (-1.98%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

STTK stock chart

Technical analysis

Key statistics

All statistics
Market cap
$454.22M
EPS (TTM)
-$0.47
52-week range
1.93 – 8.33
Day range
4.42 – 4.68
Volume / Avg
1.03M / 1.20M
Beta
—

52-week range

$1.93$8.33

STTK stock today

Shattuck Labs (STTK) closed at $4.46 on Nov 20, down 1.98% (-$0.09), versus the S&P 500's 3.70% decline. At this level, STTK sits in the middle of its 52-week range of $1.93 to $8.33: 46.5% below the high, set on Apr 20, 2026 and 131.1% above the low. STTK is up 22.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 119.7%.

Shattuck Labs has posted a net loss over the last twelve months (EPS of -$0.47), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Shattuck Labs

Company profile

Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Taylor H. Schreiber M.D., Ph.D.
Headquarters
Austin, TX
Employees
40
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Shattuck Labs generated $1.0 million in revenue, down 82.5% from fiscal 2024, its first annual decline since 2022. Shattuck Labs reported a net loss of $48.8 million, compared with a loss of $75.4 million a year earlier. Operating margin was -5150.8%.

Shattuck Labs annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$1.00M$5.72M$1.66M$652.00K$30.02M
Growth-82.52%+245.26%+154.14%-97.83%+202.16%
Net income$-48.81M$-75.41M$-87.30M$-101.94M$-44.97M
EPS (diluted)$-0.70$-1.49$-2.05$-2.41$-1.07

Analyst forecast

Forecast

Consensus (12 analysts)

strong_buy

Avg. price target

$15.40+245.29%

  • Strong buy 3
  • Buy 9
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $10.00High $19.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.14 vs $-0.10
Surprise
-40.00%

STTK news

All STTK news

Shattuck Labs peers

Health Care sector
STTK peer companies
CompanyPrice% ChgMarket capCompare
BLSMBlossomHill Therapeutics Inc.14.51+0.69%$461.20Mvs STTK
RZLTRezolute Inc.3.92-6.67%$465.58Mvs STTK
GYREGyre Therapeutics Inc.4.21-6.86%$460.79Mvs STTK
MNPRMonopar Therapeutics Inc.69.00-1.84%$467.60Mvs STTK
NGNENeurogene Inc.22.15-3.40%$458.53Mvs STTK
EVOEvotec SE ADR1.32-8.97%$469.11Mvs STTK
ASMBAssembly Biosciences Inc.22.19-1.38%$454.39Mvs STTK
KMDAKamada Ltd.7.74-1.15%$446.85Mvs STTK

Indexes, lists and sector

Shattuck Labs stock FAQ

What is Shattuck Labs's stock price today?

STTK last traded at $4.46 as of Nov 20, 4:00 PM EST, down 1.98% on the day. Prices are delayed at least 15 minutes.

Who is Shattuck Labs's CEO?

Dr. Taylor H. Schreiber M.D., Ph.D. is the chief executive officer of Shattuck Labs Inc., which has about 40 employees.

What is the STTK 52-week high?

The 52-week high for STTK is $8.33 and the 52-week low is $1.93. The stock is currently 46.5% below its high.

Compare STTK